Macquarie Group LTD Prothena Corp Public LTD CO Transaction History

Macquarie Group LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $279,908 - $455,822	5,800 Added 20.3%	34,369 $2.35 Million
Q4 2022 Feb 21, 2023	BUY	$52.05 - $65.0 $1.44 Million - $1.8 Million	27,702 Added 3195.16%	28,569 $1.72 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $17,133 - $41,289	-681 Reduced 43.99%	867 $94,000
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $74,613 - $122,121	1,548 New	1,548 $110,000

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.